AbCellera Biologics (ABCL) Operating Expenses (2020 - 2026)

AbCellera Biologics has reported Operating Expenses for 7 years, with the latest figure at $65.8 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 1.59% year-over-year to $65.8 million; the trailing twelve-month figure through Mar 2026 stood at $291.2 million (down 15.76% YoY), and the FY2025 full-year result was $292.2 million, down 14.95% from the prior year.
• Operating Expenses for Q1 2026 stood at $65.8 million, down from $73.4 million in the prior quarter.
• The five-year high for Operating Expenses was $100.8 million in Q2 2024, with the low at $54.3 million in Q2 2022.
• Historically, Operating Expenses has averaged $73.3 million across 5 years, with a median of $66.9 million in 2025.
• Annual changes were most pronounced in 2022 — Operating Expenses soared 105.14% — and 2025, when it sank 33.85%.
• AbCellera Biologics' Operating Expenses stood at $59.3 million in 2022, then climbed by 26.82% to $75.2 million in 2023, then increased by 3.42% to $77.8 million in 2024, then fell by 5.62% to $73.4 million in 2025, then slipped by 10.35% to $65.8 million in 2026.
• The last three Operating Expenses figures came in at $65.8 million (Q1 2026), $73.4 million (Q4 2025), and $85.2 million (Q3 2025), per Business Quant data.